Search - tctmd.com

Displaying 61 - 80 of 181

Sort: Relevancy | Date

News Features

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

Todd Neale

November 08, 2015

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

PANDA III: A Prospective Randomized Trial of Two Sirolimus-Eluting Bioresorbable-Polymer-Based Metallic Stents With Varying Elution and Absorption Kinetics

Presenter: Cindy L. Grines, Bo Xu

October 14, 2015

Presentation TCT 2015

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

Presenter: Bo Xu

October 14, 2015

News Industry News

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

Presentation TCT 2015

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

Presenter: Stephen G. Ellis, Lorenz Raber, Kengo Tanabe

October 13, 2015

Presentation TCT 2015

TCT 60: Long Coronary Lesions Treated With a Bioresorbable-Polymer Drug-Eluting Stent Experience From eNOBORI Registry

Presenter: Sigmund Silber, Philip M. Urban, Evgeny Kretov

October 13, 2015

News Conference News TCT 2015

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

October 13, 2015

News Industry News

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

News Industry News

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

October 12, 2015

News Industry News

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

October 12, 2015

Presentation TCT 2015

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Presenter: Carlo Di Mario, Eberhard Grube, Daniel I. Simon

October 11, 2015

Presentation TCT 2015

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? YES!

Presenter: Carlo Di Mario, Eberhard Grube, Manel Sabate

October 11, 2015

Presentation TCT 2015

Case 2: A Case Where Metallic DES Was Preferred Over BVS

Presenter: Carlo Di Mario, Eberhard Grube, Nicolas M. Van Mieghem

October 11, 2015

Presentation TCT 2015

Case 1: A Case Where BVS Was Preferred Over Metallic DES

Presenter: Carlo Di Mario, Eberhard Grube, Azeem Latib

October 11, 2015

News Conference News TCT 2015

Novel Devices Present New Treatment Options for STEMI

Yael L. Maxwell

October 11, 2015

Advertisement

From Great to Greater: Innovation in Stent Technology Possible, Worth Pursuing

My Takeaways From TCT 2015

PANDA III: A Prospective Randomized Trial of Two Sirolimus-Eluting Bioresorbable-Polymer-Based Metallic Stents With Varying Elution and Absorption Kinetics

PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics

Study From China Examines Clinical Outcomes Of Two Drug-Eluting Stents With Bioresorbable Polymers Employing Different Elution And Absorption Rates

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

TCT 15: Multislice Computed Tomography Assessment of Absorb Bioresorbable Vascular Scaffold in Comparison With Metallic Drug-Eluting Stents Data From the ABSORB Japan Trial

TCT 60: Long Coronary Lesions Treated With a Bioresorbable-Polymer Drug-Eluting Stent Experience From eNOBORI Registry

CENTURY II: Bioresorbable-Polymer DES Safe, Effective at 2 Years

Clinical Trial Demonstrates That A Bioresorbable Scaffold is Non-Inferior To A Drug-Eluting Stent In Chinese Patients With Coronary Artery Disease

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

ABSORB III: Clinical Trial Demonstrates That A Bioresorbable Scaffold Is Non-Inferior To A Drug-Eluting Stent In Patients With Coronary Artery Disease

ABSORB II: Two-Year Data From The First Randomized Comparison Between Bioresorbable Vascular Scaffolds and Everolimus-Eluting Metallic Stents Show Comparable Patient Outcomes

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? NO!

Debate: Will Bioresorbable Scaffolds Replace Metallic Stents in the Majority of Cases? YES!

Case 2: A Case Where Metallic DES Was Preferred Over BVS

Case 1: A Case Where BVS Was Preferred Over Metallic DES

Novel Devices Present New Treatment Options for STEMI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content